{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:48:58Z","timestamp":1788594538601,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Oral nimodipine is the only drug approved in North America for patients with aneurysmal subarachnoid hemorrhage (aSAH). However, bioavailability is variable and frequently poor, leading to fluctuations in peak plasma concentrations that cause dose-limiting hypotension. Furthermore, administration is problematic in patients who cannot swallow. An oral liquid formulation exists but causes diarrhea. An intravenous nimodipine formulation (GTX-104) has been developed that has bioavailability approaching 100% and is not affected by feeding or gastrointestinal absorption. GTX-104 causes less hypotension and has more consistent peak plasma concentrations than oral nimodipine in human volunteers. Herein, we describe the protocol of a prospective, randomized, open-label safety, and tolerability study of GTX-104 compared with oral nimodipine in patients with aSAH (Safety and Tolerability of GTX-104 [Nimodipine Injection for Intravenous Infusion] Compared with Oral Nimodipine; ClinicalTrials.gov identifier: NCT05995405). The study is designed to seek approval of GTX-104 by the Food and Drug Administration 505(b)(2) pathway. Inclusion and exclusion criteria match the prescribing information for oral nimodipine and include adult patients with aSAH of all Hunt and Hess grades who can receive investigational product within 96\u00a0h of aSAH. Study participants at imminent risk of death will be excluded. Study participants will be randomly assigned 1:1 to receive GTX-104 or oral nimodipine for up to 21\u00a0days. The primary end point is the proportion of study participants with clinically significant hypotension, defined as hypotension requiring treatment that has a reasonable likelihood of being due to investigational product as determined by an independent, blinded end point adjudication committee. No statistical analysis of the end point is planned. Secondary end points include all episodes of hypotension, all adverse events, delayed cerebral ischemia, rescue therapy, and suicidal ideation. Clinical and health economic outcomes include quality of life using the EuroQol 5-dimension\/3-level, modified Rankin Scale score at 30 and 90\u00a0days after aSAH and hospital resource use. The planned sample size is 100 study participants across 25 sites in the United States and Canada.<\/jats:p>","DOI":"10.1007\/s12028-024-02207-8","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T20:53:04Z","timestamp":1738097584000},"page":"1107-1117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Description of STRIVE-ON Study Protocol: Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Phase III Trial (STRIVE-ON)"],"prefix":"10.1007","volume":"42","author":[{"given":"Alex H.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry Y.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Ducruet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Taylor","family":"Kimberly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4024-8070","authenticated-orcid":false,"given":"R.","family":"Loch Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A.","family":"Rabinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"issue":"3","key":"2207_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"issue":"7","key":"2207_CR2","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1161\/STR.0000000000000436","volume":"54","author":"BL Hoh","year":"2023","unstructured":"Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 Guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the american heart association\/american stroke association. Stroke. 2023;54(7):e314\u201370. https:\/\/doi.org\/10.1161\/STR.0000000000000436.","journal-title":"Stroke"},{"issue":"4","key":"2207_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40268-020-00322-3","volume":"20","author":"SH Mahmoud","year":"2020","unstructured":"Mahmoud SH, Ji X, Isse FA. Nimodipine pharmacokinetic variability in various patient populations. Drugs RD. 2020;20(4):307\u201318. https:\/\/doi.org\/10.1007\/s40268-020-00322-3.","journal-title":"Drugs RD."},{"issue":"1","key":"2207_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.18433\/jpps30960","volume":"23","author":"FA Isse","year":"2020","unstructured":"Isse FA, Abdallah YEH, Mahmoud SH. The impact of nimodipine administration through feeding tube on outcomes in patients with aneurysmal subarachnoid hemorrhage. J Pharm Pharm Sci Publ Can Soc Pharm Sci Soc Can Sci Pharm. 2020;23(1):100\u20138. https:\/\/doi.org\/10.18433\/jpps30960.","journal-title":"J Pharm Pharm Sci Publ Can Soc Pharm Sci Soc Can Sci Pharm."},{"issue":"4","key":"2207_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/phar.2791","volume":"43","author":"SH Mahmoud","year":"2023","unstructured":"Mahmoud SH, Hefny FR, Panos NG, et al. Comparison of nimodipine formulations and administration techniques via enteral feeding tubes in patients with aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study. Pharmacotherapy. 2023;43(4):279\u201390. https:\/\/doi.org\/10.1002\/phar.2791.","journal-title":"Pharmacotherapy"},{"issue":"3 Suppl","key":"2207_CR6","first-page":"407","volume":"22","author":"NW Dorsch","year":"1993","unstructured":"Dorsch NW, Compton JS. Treatment of symptomatic vasospasm with nimodipine. Ann Acad Med Singap. 1993;22(3 Suppl):407\u20139.","journal-title":"Ann Acad Med Singap"},{"issue":"1","key":"2207_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12028-015-0230-x","volume":"25","author":"N Sandow","year":"2016","unstructured":"Sandow N, Diesing D, Sarrafzadeh A, Vajkoczy P, Wolf S. Nimodipine dose reductions in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2016;25(1):29\u201339. https:\/\/doi.org\/10.1007\/s12028-015-0230-x.","journal-title":"Neurocrit Care"},{"issue":"5","key":"2207_CR8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00701-015-2369-9","volume":"157","author":"T Abboud","year":"2015","unstructured":"Abboud T, Andresen H, Koeppen J, et al. Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage. Acta Neurochir Wien. 2015;157(5):763\u20137. https:\/\/doi.org\/10.1007\/s00701-015-2369-9.","journal-title":"Acta Neurochir Wien."},{"issue":"8","key":"2207_CR9","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.04.024","volume":"28","author":"A Hajizadeh Barfejani","year":"2019","unstructured":"Hajizadeh Barfejani A, Rabinstein AA, Wijdicks EFM, Clark SL. Poor utilization of nimodipine in aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2019;28(8):2155\u20138. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2019.04.024.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"2207_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12028-019-00676-w","volume":"31","author":"M Kieninger","year":"2019","unstructured":"Kieninger M, Gruber M, Knott I, et al. Incidence of arterial hypotension in patients receiving peroral or continuous intra-arterial nimodipine after aneurysmal or perimesencephalic subarachnoid hemorrhage. Neurocrit Care. 2019;31(1):32\u20139. https:\/\/doi.org\/10.1007\/s12028-019-00676-w.","journal-title":"Neurocrit Care"},{"issue":"3","key":"2207_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12028-012-9670-8","volume":"16","author":"HA Choi","year":"2012","unstructured":"Choi HA, Ko SB, Chen H, et al. Acute effects of nimodipine on cerebral vasculature and brain metabolism in high grade subarachnoid hemorrhage patients. Neurocrit Care. 2012;16(3):363\u20137. https:\/\/doi.org\/10.1007\/s12028-012-9670-8.","journal-title":"Neurocrit Care"},{"issue":"4","key":"2207_CR12","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1161\/STROKEAHA.119.027396","volume":"51","author":"AP Carlson","year":"2020","unstructured":"Carlson AP, H\u00e4nggi D, Wong GK, et al. Single-Dose Intraventricular nimodipine microparticles versus oral nimodipine for aneurysmal subarachnoid hemorrhage. Stroke. 2020;51(4):1142\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.119.027396.","journal-title":"Stroke"},{"key":"2207_CR13","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1016\/j.wneu.2021.11.016","volume":"158","author":"L Mahmoud","year":"2022","unstructured":"Mahmoud L, Zullo AR, Blake C, et al. Safety of modified nimodipine dosing in aneurysmal subarachnoid hemorrhage. World Neurosurg. 2022;158:e501\u20138. https:\/\/doi.org\/10.1016\/j.wneu.2021.11.016.","journal-title":"World Neurosurg."},{"key":"2207_CR14","doi-asserted-by":"crossref","unstructured":"Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. In: Cochrane Database Syst Rev. 2007;(3):CD000277.","DOI":"10.1002\/14651858.CD000277.pub3"},{"key":"2207_CR15","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2147\/IJN.S226591","volume":"15","author":"S Huang","year":"2020","unstructured":"Huang S, Huang Z, Fu Z, et al. A novel drug delivery carrier comprised of nimodipine drug solution and a nanoemulsion: preparation, characterization, in vitro, and in vivo studies. Int J Nanomedicine. 2020;15:1161\u201372. https:\/\/doi.org\/10.2147\/IJN.S226591.","journal-title":"Int J Nanomedicine"},{"issue":"1\u20132","key":"2207_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/BF02188783","volume":"137","author":"F Porchet","year":"1995","unstructured":"Porchet F, Chiolero R, de Tribolet N. Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien). 1995;137(1\u20132):62\u20139.","journal-title":"Acta Neurochir (Wien)"},{"issue":"5","key":"2207_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2044.1997.112-az0105.x","volume":"52","author":"D Radhakrishnan","year":"1997","unstructured":"Radhakrishnan D, Menon DK. Haemodynamic effects of intravenous nimodipine following aneurysmal subarachnoid haemorrhage: implications for monitoring. Anaesthesia. 1997;52(5):489\u201391.","journal-title":"Anaesthesia"},{"issue":"6","key":"2207_CR18","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1227\/01.NEU.0000215868.40441.D9","volume":"58","author":"R Schmid-Elsaesser","year":"2006","unstructured":"Schmid-Elsaesser R, Kunz M, Zausinger S, Prueckner S, Briegel J, Steiger HJ. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. Neurosurgery. 2006;58(6):1054\u201365. .","journal-title":"Neurosurgery"},{"key":"2207_CR19","doi-asserted-by":"publisher","first-page":"e834","DOI":"10.1016\/j.wneu.2019.08.001","volume":"132","author":"S Hern\u00e1ndez-Dur\u00e1n","year":"2019","unstructured":"Hern\u00e1ndez-Dur\u00e1n S, Mielke D, Rohde V, Malinova V. Does Nimodipine Interruption due to high catecholamine doses lead to a greater incidence of delayed cerebral ischemia in the setting of aneurysmal subarachnoid hemorrhage? World Neurosurg. 2019;132:e834\u201340.","journal-title":"World Neurosurg."},{"issue":"1","key":"2207_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12028-023-01760-y","volume":"39","author":"V Rass","year":"2023","unstructured":"Rass V, Kindl P, Lindner A, et al. Blood pressure changes in association with nimodipine therapy in patients with spontaneous subarachnoid hemorrhage. Neurocrit Care. 2023;39(1):104\u201315. https:\/\/doi.org\/10.1007\/s12028-023-01760-y.","journal-title":"Neurocrit Care"},{"key":"2207_CR21","unstructured":"BIONPHARMA INC. NIMODIPINE- nimodipine capsule, liquid filled. FDA approved labeling text, ANDA076740. Published online 2020."},{"key":"2207_CR22","unstructured":"Bayer PLC. NIMOTOP (0.02% Solution for Infusion) Summary of Product Characteristics. Published online 2016."},{"issue":"11","key":"2207_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1056\/NEJM198303173081103","volume":"308","author":"GS Allen","year":"1983","unstructured":"Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm\u2013a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308(11):619\u201324.","journal-title":"N Engl J Med"},{"issue":"3\u20134","key":"2207_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/BF01456369","volume":"82","author":"J Philippon","year":"1986","unstructured":"Philippon J, Grob R, Dagreou F, Guggiari M, Rivierez M, Viars P. Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir. 1986;82(3\u20134):110\u20134.","journal-title":"Acta Neurochir"},{"issue":"4","key":"2207_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3171\/jns.1988.68.4.0505","volume":"68","author":"KC Petruk","year":"1988","unstructured":"Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68(4):505\u201317.","journal-title":"J Neurosurg"},{"key":"2207_CR26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/bmj.298.6674.636","volume":"298","author":"JD Pickard","year":"1989","unstructured":"Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298:636\u201342.","journal-title":"BMJ"},{"issue":"10","key":"2207_CR27","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/STROKEAHA.110.589275","volume":"41","author":"MD Vergouwen","year":"2010","unstructured":"Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391\u20135. https:\/\/doi.org\/10.1161\/STROKEAHA.110.589275.","journal-title":"Stroke"},{"key":"2207_CR28","unstructured":"Food and Drug Administration Center for Drugs Evaluation and Research. Guidance for Industry: Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials. Published online 2012. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-suicidal-ideation-and-behavior-prospective-assessment-occurrence-clinical-trials"},{"key":"2207_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3171\/jns.1968.28.1.0014","volume":"28","author":"WE Hunt","year":"1968","unstructured":"Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg. 1968;28:14\u201320.","journal-title":"J Neurosurg"},{"key":"2207_CR30","first-page":"985","volume":"68","author":"CG Drake","year":"1988","unstructured":"Drake CG. Report of world federation of neurological surgeons committee on a universal subarachnoid hemorrhage grading scale. J neurosurg. 1988;68:985\u20136.","journal-title":"J neurosurg"},{"issue":"6","key":"2207_CR31","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1161\/STROKEAHA.110.601211","volume":"42","author":"LA Degen","year":"2011","unstructured":"Degen LA, Dorhout Mees SM, Algra A, Rinkel GJ. Interobserver variability of grading scales for aneurysmal subarachnoid hemorrhage. Stroke. 2011;42(6):1546\u20139.","journal-title":"Stroke"},{"issue":"7","key":"2207_CR32","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1161\/STROKEAHA.117.017866","volume":"48","author":"JP Broderick","year":"2017","unstructured":"Broderick JP, Adeoye O, Elm J. Evolution of the modified Rankin scale and its use in future stroke trials. Stroke. 2017;48(7):2007\u201312. https:\/\/doi.org\/10.1161\/STROKEAHA.117.017866.","journal-title":"Stroke"},{"issue":"13","key":"2207_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024296","volume":"11","author":"RA Joundi","year":"2022","unstructured":"Joundi RA, Adekanye J, Leung AA, et al. Health state utility values in people with stroke: a systematic review and meta-analysis. J Am Heart Assoc. 2022;11(13): e024296. https:\/\/doi.org\/10.1161\/JAHA.121.024296.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2207_CR34","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s12325-018-0707-z","volume":"35","author":"LS Schwartzberg","year":"2018","unstructured":"Schwartzberg LS, Navari RM. Safety of polysorbate 80 in the oncology setting. Adv Ther. 2018;35(6):754\u201367. https:\/\/doi.org\/10.1007\/s12325-018-0707-z.","journal-title":"Adv Ther"},{"issue":"12","key":"2207_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1177\/1060028015608198","volume":"49","author":"DE Lindquist","year":"2015","unstructured":"Lindquist DE, Rowe AS, Heidel E, Fleming T, Yates JR. Evaluation of the hemodynamic effects of intravenous amiodarone formulations during the maintenance phase infusion. Ann Pharmacother. 2015;49(12):1317\u201321. https:\/\/doi.org\/10.1177\/1060028015608198.","journal-title":"Ann Pharmacother"},{"issue":"7","key":"2207_CR36","first-page":"1405","volume":"50","author":"SD Pearson","year":"1993","unstructured":"Pearson SD, Trissel LA. Leaching of diethylhexyl phthalate from polyvinyl chloride containers by selected drugs and formulation components. Am J Hosp Pharm. 1993;50(7):1405\u20139.","journal-title":"Am J Hosp Pharm"},{"key":"2207_CR37","first-page":"216","volume":"41","author":"KD Ramsch","year":"1987","unstructured":"Ramsch KD, Lucker PW, Wetzelsberger N. Pharmacokinetics of intravenously and orally administered nimodipine. Clin Pharmacol Ther. 1987;41:216.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2207_CR38","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/BF00607954","volume":"30","author":"E Vinge","year":"1986","unstructured":"Vinge E, Andersson KE, Brandt L, Ljunggren B, Nilsson LG, Rosendal-Helgesen S. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. Eur J Clin Pharmacol. 1986;30(4):421\u20135.","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 1","key":"2207_CR39","first-page":"74","volume":"28","author":"KD Ramsch","year":"1985","unstructured":"Ramsch KD, Ahr G, Tettenborn D, Auer LM. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochir Stuttg. 1985;28(Suppl 1):74\u20138.","journal-title":"Neurochir Stuttg."},{"issue":"Suppl 1","key":"2207_CR40","first-page":"73","volume":"6","author":"KD Ramsch","year":"1986","unstructured":"Ramsch KD, Graefe KH, Scherling D, Sommer J, Ziegler R. Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. Am J Nephrol. 1986;6(Suppl 1):73\u201380.","journal-title":"Am J Nephrol"},{"issue":"4","key":"2207_CR41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/BF00265956","volume":"45","author":"CR Kumana","year":"1993","unstructured":"Kumana CR, Kou M, Yu YL, et al. Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage. Eur J Clin Pharmacol. 1993;45(4):363\u20136.","journal-title":"Eur J Clin Pharmacol"},{"key":"2207_CR42","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3389\/fneur.2019.01161","volume":"10","author":"C Fischer","year":"2019","unstructured":"Fischer C, Goldberg J, Vulcu S, et al. Nimodipine-induced blood pressure changes can predict delayed cerebral ischemia. Front Neurol. 2019;10:1161. https:\/\/doi.org\/10.3389\/fneur.2019.01161.","journal-title":"Front Neurol"},{"issue":"4","key":"2207_CR43","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3171\/2018.11.JNS182891","volume":"132","author":"A Pa\u013ea","year":"2019","unstructured":"Pa\u013ea A, Schick J, Klein M, et al. The influence of nimodipine and vasopressors on outcome in patients with delayed cerebral ischemia after spontaneous subarachnoid hemorrhage. J Neurosurg. 2019;132(4):1096\u2013104. https:\/\/doi.org\/10.3171\/2018.11.JNS182891.","journal-title":"J Neurosurg"},{"issue":"1","key":"2207_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10143-023-02273-0","volume":"47","author":"C Ditz","year":"2024","unstructured":"Ditz C, Matone MV, Schwachenwald B, K\u00fcchler J. Risks of nimodipine dose reduction during the high-risk period for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neurosurg Rev. 2024;47(1):37. https:\/\/doi.org\/10.1007\/s10143-023-02273-0.","journal-title":"Neurosurg Rev"},{"issue":"1\u20132","key":"2207_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF01456313","volume":"82","author":"LM Auer","year":"1986","unstructured":"Auer LM, Brandt L, Ebeling U, et al. Nimodipine and early aneurysm operation in good condition SAH patients [published erratum appears in Acta Neurochir (Wien) 1986;83(3\u20134):158]. Acta Neurochir (Wien). 1986;82(1\u20132):7\u201313.","journal-title":"Acta Neurochir (Wien)"},{"issue":"5","key":"2207_CR46","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3171\/jns.1984.61.5.0864","volume":"61","author":"B Ljunggren","year":"1984","unstructured":"Ljunggren B, Brandt L, Saveland H, et al. Outcome in 60 consecutive patients treated with early aneurysm operation and intravenous nimodipine. J Neurosurg. 1984;61(5):864\u201373.","journal-title":"J Neurosurg"},{"issue":"Suppl 1","key":"2207_CR47","first-page":"110","volume":"28","author":"E Kazner","year":"1985","unstructured":"Kazner E, Sprung C, Adelt D, et al. Clinical experience with nimodipine in the prophylaxis of neurological deficits after subarachnoid hemorrhage. Neurochirurgia (Stuttg). 1985;28(Suppl 1):110\u20133.","journal-title":"Neurochirurgia (Stuttg)."},{"issue":"1\u20132","key":"2207_CR48","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF01402363","volume":"85","author":"RW Seiler","year":"1987","unstructured":"Seiler RW, Grolimund P, Zurbruegg HR. Evaluation of the calcium-antagonist nimodipine for the prevention of vasospasm after aneurysmal subarachnoid haemorrhage. A prospective transcranial Doppler ultrasound study. Acta Neurochir Wien. 1987;85(1\u20132):7\u201316.","journal-title":"Acta Neurochir Wien."},{"issue":"1\u20132","key":"2207_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/BF01406611","volume":"94","author":"J Hillman","year":"1988","unstructured":"Hillman J, von Essen C, Leszniewski W. Results of treatment for cerebral saccular aneurysms in a small neurosurgical unit\u2013evaluation of early operation and nimodipine treatment. Acta Neurochir (Wien). 1988;94(1\u20132):28\u201331.","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"2207_CR50","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/0090-3019(88)90270-4","volume":"30","author":"L Pellettieri","year":"1988","unstructured":"Pellettieri L, Bolander H, Carlsson H, Sjolander U. Nimodipine treatment of selected good-risk patients with subarachnoid hemorrhage: no significant difference between present and historical results. Surg Neurol. 1988;30(3):180\u20136.","journal-title":"Surg Neurol"},{"issue":"2","key":"2207_CR51","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1227\/00006123-198808000-00004","volume":"23","author":"M Jan","year":"1988","unstructured":"Jan M, Buchheit F, Tremoulet M. Therapeutic trial of intravenous nimodipine in patients with established cerebral vasospasm after rupture of intracranial aneurysms [see comments]. Neurosurgery. 1988;23(2):154\u20137.","journal-title":"Neurosurgery"},{"issue":"5","key":"2207_CR52","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3171\/jns.1988.69.5.0683","volume":"69","author":"J Ohman","year":"1988","unstructured":"Ohman J, Heiskanen O. Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg. 1988;69(5):683\u20136.","journal-title":"J Neurosurg"},{"issue":"1","key":"2207_CR53","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3171\/2008.7.JNS08178","volume":"110","author":"E Kronvall","year":"2009","unstructured":"Kronvall E, Undren P, Romner B, Saveland H, Cronqvist M, Nilsson OG. Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration. J Neurosurg. 2009;110(1):58\u201363. https:\/\/doi.org\/10.3171\/2008.7.JNS08178.","journal-title":"J Neurosurg"},{"issue":"1\u20132","key":"2207_CR54","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.wneu.2011.09.030","volume":"78","author":"V Soppi","year":"2012","unstructured":"Soppi V, Karamanakos PN, Koivisto T, et al. A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage. World Neurosurg. 2012;78(1\u20132):101\u20139.","journal-title":"World Neurosurg."}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-024-02207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-024-02207-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-024-02207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T15:27:45Z","timestamp":1749050865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-024-02207-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2207"],"URL":"https:\/\/doi.org\/10.1007\/s12028-024-02207-8","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HA Choi, SH-Y Chou, AF Ducruet, WT Kimberly and AA Rabinstein are members of the Scientific Advisory Board of Grace Therapeutics. HA Choi, SH-Y Chou, AF Ducruet and WT Kimberly are consultants for and have stock options in Grace Therapeutics. RL Macdonald is Chief Medical Officer, an employee of and has stock options in Grace Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"We confirm adherence to ethical guidelines and indicate ethical approvals and use of informed. consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval\/informed consent"}}]}}